Two kinds of shoulder replacement for shoulder osteoarthritis compared
Compares reverse and standard shoulder replacement in people with shoulder osteoarthritis.
Key facts
- Who runs it
- La Tour Hospital
- Where
- Meyrin, SwitzerlandSee the site
- Trial code
- Registry title
- Anatomic TSA vs RTSA for Glenohumeral Arthritis
- Status
- Recruiting
- People taking part
- 296 people, planned
- Started
- 1 Sept 2020
- Expected to end
- 1 May 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Total shoulder arthroplasty
- Record updated
- 22 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 65 to 85 with primary shoulder joint arthritis (glenohumeral osteoarthritis) and an intact rotator cuff. They will get either an anatomic or a reverse total shoulder replacement.
- Age
- 65 to 85 years
- Sex
- All sexes
- Disease stage
- Primary glenohumeral arthritis with an intact rotator cuff and no important bone loss in the shoulder socket (glenoid).
- Earlier treatment
- People who had earlier shoulder surgery or revision surgery cannot join.
Main reasons for not taking part
- B2 glenoid with > 80% posterior humeral head subluxation or more than 25 degrees neoglenoid retroversion, or B3 and C type glenoids
- Full thickness rotator cuff tear, non-functioning deltoid muscle or axillary nerve damage
- Acute or badly healed upper arm bone fracture, or a chronic locked dislocation
- Rheumatoid arthritis, tumors, infection or neuropathic joints
- Drug or alcohol abuse, or not able to follow the study procedures, for example due to dementia, language problems or not being able to have a CT scan
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Primary glenohumeral arthritis,
- Intact rotator cuff,
- No important glenoid bone loss (cf exclusion criteria),
- Patients between 65 and 85 years old
- Informed Consent as documented by signature (Appendix Informed Consent Form)
Who cannot take part
- Revision surgery or surgical antecedents,
- Known or suspected non-compliance, drug or alcohol abuse,
- Infection and neuropathic joints,
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, contraindication for CT scan etc. of the participant,
- B2 glenoid with > 80% posterior humeral head subluxation or greater 25 degrees neoglenoid retroversion,
- B3 and C type glenoids,
- Full thickness rotator cuff tear,
- Acute or malunited proximal humeral fracture,
- Chronic locked dislocation
- Rheumatoid arthritis,
- Tumors,
- Axillary nerve damage,
- Non-functioning deltoid muscle,
- Glenoid vault deficiency precluding baseplate fixation,
- Patients incapable of judgement or under tutelage,
- Enrolment of the investigator, his/her family members, employees and other dependent persons
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 65 and 85 years old?
Where in Switzerland
- La Tour HospitalMeyrin, SwitzerlandContact: Alexandre Lädermann, MDTaking people
About the trial
What the trial wants to find out
There are no published prospective studies that compared 2-year functional outcomes of RTSA and anatomic TSA for the treatment of primary glenohumeral osteoarthritis with intact rotator cuffs and no excessive glenoid retroversion. The primary goal of our prospective randomized study is to determine whether RTSA have at least as good results as anatomic TSA (non-inferiority), in patients with glenohumeral osteoarthritis, without rotator cuff tears nor significant glenoid retroversion.
The 2 groups in the trial
- Anatomic TSAExisting treatment, for comparison
The control group will receive through a deltopectoral approach an anatomic total shoulder arthroplasty (TSA) for a primary glenohumeral arthritis
Treatment: Total shoulder arthroplasty
- RTSATreatment being tested
The experimental group will receive through a deltopectoral approach a reverse total shoulder arthroplasty RTSA for a primary glenohumeral arthritis
Treatment: Total shoulder arthroplasty
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Anatomic Versus Reverse Shoulder Arthroplasty for Primary Glenohumeral Osteoarthritis. A Randomized Prospective Study
- Plain-language title
- Two kinds of shoulder replacement for shoulder osteoarthritis comparedGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT04629391, who can take part
- Record updated
- 22 May 2026